🔗 Share this article

Given that the United States undertakes historic changes to its immunization recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has focused upon alleged deaths after Covid immunization in her recent position at the FDA.

Scheduled Shifts to Childhood Vaccine Schedule

Agency leaders planned to reveal radical changes to the childhood immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with much of the international standard with no evidence for public health gain. The planned update has been postponed until the coming year.

Rather than Vinay Prasad, Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this year.

A Shift at the Agency

This interim role might represent a closer partnership between the drug and biologics branches as Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific pediatric immunization guidelines in the US so as to align more similar to Denmark, a nation with comprehensive healthcare and a population roughly the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has little discernible experience in pharmaceutical research, regulation or administrative roles, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “understand legal statutes and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

CDER has an immense portfolio at the FDA, the former commissioner emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office authorizes a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and every single one have to be looked after,” Dr. Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial management element to the job, which supervises over 5,000 staff members. “It’s a huge management job, if you perform it correctly,” Woodcock added.

Official Statement and Contentious Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment represents more teamwork among FDA leaders on vaccines, a press secretary stated that the “questions stem from flawed presumptions”.

“This background aligns with the functions of her position,” the official said, citing the period Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed rapid therapy clearance system that apparently troubled her former heads. “By what process are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed rules of all drugs, with the exception of vaccines.”

Documented History on Vaccines

Concerning vaccines, Høeg has a clearer, if problematic, history, Howard said. She authored a research paper using non-validated volunteer-provided data to determine the frequency of myocarditis following COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the incoming administration encompassed altering rules for new vaccines and discontinuing “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from getting Covid vaccines.

“She is an thorough dogmatist who commences with her beliefs and tailors the evidence to retrofit the evidence in a extremely disingenuous, dishonest way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|